Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570751 | 0.90 | CYP3A4 (0.51) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL24536233 | 0.88 | CYP2D6 (0.52) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL24536218 | 0.82 | CYP2D6 (0.50) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL1586461 | 0.80 | CYP3A4 (0.59) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL3493144 | 0.80 | CYP2D6 (0.54) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL7500958 | 0.79 | CYP2D6 (0.56) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL23285195 | 0.79 | CYP2D6 (0.48) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL9749110 | 0.78 | MAOA (0.56) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL13201417 | 0.76 | CYP3A4 (0.50) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 | |
| SCHEMBL13201457 | 0.76 | CYP3A4 (0.50) | CYP2D6CYP3A4TSHRSIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | CYP2D6 124/4885CYP3A4 63/4885TSHR 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.